Experimental cancer therapy targets tough tumors with radioactive precision
NCT ID NCT05130255
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested a two-step radioimmunotherapy combining GD2-SADA and 177Lu-DOTA in patients with recurrent or metastatic solid tumors, including small cell lung cancer, high-risk neuroblastoma, sarcoma, and melanoma. The goal was to assess safety and find the right dose. The study was terminated early after enrolling 23 participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GD2-SADA and 177Lu-DOTA (two-step radioimmunotherapy)
What this could lead to
If successful, this could point toward a new treatment option for patients with hard-to-treat cancers that express GD2.
What could go wrong
This was an early, terminated Phase 1 trial with only 23 participants, so results are limited. The approach may not prove effective or safe in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Case Western Reserve University, Cleveland
Cleveland, Ohio, 44106, United States
-
City of Hope National Medical Center
Duarte, California, 91010, United States
-
Corewell Health-BAMF Health
Grand Rapids, Michigan, 49503, United States
-
HonorHealth
Scottsdale, Arizona, 85258, United States
-
Memorial Sloan- Kettering Cancer Center
New York, New York, 10065, United States
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15260, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Wisconsin-Madison
Madison, Wisconsin, 53705, United States